We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+39.74%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$210M
AUM Growth
+$79.2M
(+60%)
Cap. Flow
+$42M
Cap. Flow
% of AUM
19.96%
Top 10 Holdings %
Top 10 Hldgs %
63.23%
Holding
36
New
15
Increased
9
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$9.59M |
| 2 |
Arvinas
ARVN
|
+$5.57M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.5M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$5.47M |
| 5 |
DERM
Dermira, Inc.
DERM
|
+$5.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$6.31M |
| 2 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$2.24M |
| 3 |
Veracyte
VCYT
|
+$1.16M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$728K |
| 5 |
Outlook Therapeutics
OTLK
|
+$15K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$1.93B
| $28M | 13.31% |
2,944,201
-75,000
| -2% | -$728K |
|
|
KDMN
2
DELISTED
Kadmon Holdings, Inc.
KDMN
| $20.2M | 9.58% |
7,635,000
+97,000
| +1% | +$245K |
|
3
Assembly Biosciences
ASMB
$503M
| $15M | 7.12% |
63,375
+3,500
| +6% | +$886K |
|
|
CASM
4
DELISTED
CAS Medical Systems, Inc.
CASM
| $12.8M | 6.08% |
5,263,508
| – | – |
|
|
5
Insmed
INSM
$21.3B
| $10.8M | 5.11% |
+370,000
| New | +$9.59M |
|
|
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $10.6M | 5.04% |
206,000
+18,500
| +10% | +$799K |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $9.61M | 4.57% |
500,000
+100,000
| +25% | +$1.61M |
|
|
8
Veracyte
VCYT
$3.58B
| $9.54M | 4.54% |
381,500
-61,000
| -14% | -$1.16M |
|
|
DERM
9
DELISTED
Dermira, Inc.
DERM
| $8.63M | 4.1% |
+636,500
| New | +$5.31M |
|
10
argenx
ARGX
$52B
| $7.93M | 3.77% |
63,500
+10,500
| +20% | +$1.23M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $6.87M | 3.27% |
+517,500
| New | +$5.5M |
|
|
VRAY
12
DELISTED
ViewRay, Inc.
VRAY
| $6.02M | 2.86% |
815,000
+503,500
| +162% | +$3.88M |
|
|
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
| $5.88M | 2.8% |
205,500
+32,500
| +19% | +$705K |
|
|
14
Enanta Pharmaceuticals
ENTA
$377M
| $5.83M | 2.77% |
+61,000
| New | +$5.47M |
|
15
Xenon Pharmaceuticals
XENE
$6.02B
| $5.61M | 2.67% |
552,500
+15,000
| +3% | +$127K |
|
16
IRIDEX
IRIX
$14.4M
| $5.36M | 2.55% |
1,174,500
| – | – |
|
|
DRNA
17
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $4.82M | 2.29% |
+328,825
| New | +$3.78M |
|
|
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
| $4.82M | 2.29% |
+91,900
| New | +$3.72M |
|
|
19
Arvinas
ARVN
$520M
| $4.63M | 2.2% |
+314,000
| New | +$5.57M |
|
20
Protagonist Therapeutics
PTGX
$8.51B
| $4.24M | 2.02% |
+337,500
| New | +$2.98M |
|
21
Alector
ALEC
$168M
| $3.74M | 1.78% |
+200,000
| New | +$3.78M |
|
|
ACER
22
DELISTED
Acer Therapeutics Inc
ACER
| $3.57M | 1.7% |
147,000
+4,000
| +3% | +$94.4K |
|
23
Arrowhead Research
ARWR
$12.1B
| $3.07M | 1.46% |
+167,500
| New | +$2.76M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3M | 1.43% |
+41,000
| New | +$2.79M |
|
|
BHVN
25
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.57M | 1.22% |
50,000
-3,800
| -7% | -$164K |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q1 2019 Portfolio in Review
As of Q1 2019, Acuta Capital Partners held 36 positions worth $210M, up 60% from $131M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Acuta Capital Partners deployed $42M of net new capital in Q1 2019, opening 15 new positions and adding to 9 existing holdings. Its largest new stake was Insmed: 370,000 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier.
On the sell side, the largest reduction was Amarin Corp, an estimated $6.31M trimmed.
- Acuta Capital Partners's largest Q1 2019 buy was Insmed: 370,000 shares worth $10.8M.
- Acuta Capital Partners added most to ViewRay, Inc. in Q1 2019, an estimated $3.88M increase.
- Acuta Capital Partners's biggest Q1 2019 reduction was Amarin Corp, cutting an estimated $6.31M.
- Acuta Capital Partners fully exited Outlook Therapeutics in Q1 2019, selling an estimated $15K.
- Acuta Capital Partners's ten largest holdings make up 63% of its $210M portfolio in Q1 2019.
- Acuta Capital Partners opened 15 new positions and closed 3 in Q1 2019.
- Acuta Capital Partners's portfolio value rose 60% quarter-over-quarter to $210M.
Based on Acuta Capital Partners's 13F filing for Q1 2019, filed 14 May 2019.